本帖最后由 老马 于 2012-1-13 21:20 编辑 # O5 s6 X2 {5 L
/ p. i% p3 y. D0 W# ]爱必妥和阿瓦斯丁的比较: Z* ~/ z5 Z4 z* T
+ l4 H+ E# W- Q/ chttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 F' E% y; j9 k g f1 I
' g% B2 A x' T; D
6 G; A( N" T1 [4 P
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
# y7 M' @& ]$ Y0 \( t; x==================================================
6 P2 J! Y& W- S: S* a2 vOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
0 H) P& k2 o9 Y$ h2 z9 H4 b7 `Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
0 R* b0 r! O- d. w1 _, _/ OResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.+ T% f" x5 E3 E
|